Ajit Mishra, vice president, research, Religare Broking, answers your stockmarket queries.
The Sensex ended lower on unfavourable cues.
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
The FMCG index gained more than 1% on the back of stellar gains in ITC.
Face NPPA fine for overcharging on anti-asthma drug
Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally
Fabiflu sales have grown by 62 per cent in July. It was launched in June. This drug is being used by doctors for mild-to-moderate Covid patients even if they are in home isolation.
Russia's central bank early on Tuesday raised interest rates to 17 per cent to counter the 50 per cent rouble fall in six months.
The S&P BSE Sensex ended 46 points lower at 24,824 and Nifty50 settled at 7,555, down by 8 points after hitting intra-day high of 7,600.45.
Currency played an important role in Q2, with US dollar, Japanese yen and euro appreciating vis-a-vis the Indian rupee, while the Brazilian real, South African rand and Russian ruble depreciating against rupee.
The BSE Mid-Cap index was currently up 0.81%.
.jpg)
In a letter to health minister Harsh Vardhan, the Indian Pharmaceutical Alliance, an industry body representing leading pharma companies, including Sun Pharma, Lupin, Dr Reddy's Labs, Cadila Health and Glenmark, stressed the need for an out-of-court settlement with health activists fighting for the rights of clinical trial participants.
Indian pharma firms under European drug regulator's scanner.
Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D.
Low growth visibility and trouble with regulators have resulted in lack of interest from investors
From rising prescriptions to the pharma sales force back on the field with full vigour and companies finally finding their feet with the digital marketing strategies - Indian drug makers have shown that medicine sales is certainly a sunshine sector.
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
Popular antacid Mucaine Gel, manufactured by Pfizer's subsidiary Wyeth Laboratories, was also found laced with the heavy metals as well as cadmium.
Experts say the stock market correction in recent times increases the risk-reward in favour of large-cap stocks.
Revival in domestic business should also help overall revenue growth.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.
Index heavyweight RIL surged 3% to end above Rs 1,000 mark while IT majors were also the top gainers.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries:
FIIs are looking at the long-term story and initiatives of Indian pharma companies to transform themselves into global entities.
The Sensex ended at at 27,676, lower by 210 points and the Nifty broke the psychological level of 8,400 to end at 83877 down 70 points.
Geopolitical concerns, earnings sees investors rush to safe haven plays post the Union Budget presentation in July.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
Another year of strong performance by these export-oriented sectors likely as US economy revives and rupee is expected to be under pressure.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers's queries on stocks they own or want to buy.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances